|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM220223009 |
| 003 |
DE-627 |
| 005 |
20250214080357.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2012 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2012.07.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0734.xml
|
| 035 |
|
|
|a (DE-627)NLM220223009
|
| 035 |
|
|
|a (NLM)22892399
|
| 035 |
|
|
|a (PII)S1521-6616(12)00182-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zanotti, Cinzia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.11.2012
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2012 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The anti-α4 monoclonal antibody natalizumab inhibits lymphocyte extravasation into the central nervous system and increases peripheral T and B lymphocytes in multiple sclerosis patients. To investigate whether the lymphocyte accumulation was due to a higher lymphocyte production, an altered homeostasis, or a differential transmigration of lymphocyte subsets through endothelia, T-cell receptor excision circles and kappa-deleting recombination excision circles were quantified before and after treatment, T-cell receptor repertoire was analyzed by spectratyping, and T- and B-lymphocyte subset migration was studied using transwell coated with vascular and lymphatic endothelial cells. We found that the number of newly produced T and B lymphocytes is increased because of a high release and of a low propensity of naïve subsets to migrate across endothelial cells. In some patients this resulted in an enlargement of T-cell heterogeneity. Because new lymphocyte production ensures the integrity of immune surveillance, its quantification could be used to monitor natalizumab therapy safety
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Natalizumab
|2 NLM
|
| 650 |
|
7 |
|a Protein Isoforms
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
| 700 |
1 |
|
|a Chiarini, Marco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Serana, Federico
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sottini, Alessandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Garrafa, Emirena
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Torri, Fabio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Caimi, Luigi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rasia, Sarah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Capra, Ruggero
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Imberti, Luisa
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 145(2012), 1 vom: 04. Okt., Seite 19-26
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:145
|g year:2012
|g number:1
|g day:04
|g month:10
|g pages:19-26
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2012.07.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 145
|j 2012
|e 1
|b 04
|c 10
|h 19-26
|